Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marcelo C Pasquini, MD, MS
Medical College of Wisconsin
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope National Medical Center
Duarte, California, United States
- Stanford Hospital and Clinics
Palo Alto, California, United States
- University of California, San Francisco
San Francisco, California, United States
- H. Lee Moffitt Cancer Center
Tampa, Florida, United States
- Loyola University Medical Center
Maywood, Illinois, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Roswell Park Cancer Center
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Mount Sinai Medical Center
New York, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- University of Pennsylvania Hospital Center
Philadelphia, Pennsylvania, United States
- Baylor College and Medicine
Houston, Texas, United States
- University of Virginia
Charlottesville, Virginia, United States
- University of Wisconsin Hospitals and Clinics
Madison, Wisconsin, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Jan 2022
- Primary completion
- 22 Aug 2024
- Completion
- 20 Feb 2025
- Last update posted
- 19 May 2026
- Registered enrollment
- 40
- Registry id
- NCT05032820
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.